<p>随着全球市场在不断变化的贸易政策和货币调整中航行，亚洲市场凭借其多样的经济活动和强劲的股票表现继续吸引关注。在这样的背景下，虽然 “便士股票” 是一个较老的术语，但仍然是投资者寻求小型或新兴公司潜在增长的焦点。通过识别那些财务健康状况良好的公司，投资者可以发现平衡风险与潜在回报的机会。</p>
<h3>亚洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲便士股票筛选器的 977 只股票完整列表。</p>
<p>让我们回顾一些我们筛选出的显著股票。</p>
<h2>嘉华国际控股 (SEHK:173)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 嘉华国际控股有限公司是一家投资控股公司，涉及香港和中国大陆的房地产开发和投资，市值约为 HK$77.9 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自中国大陆的房地产开发（HK$59.1 亿）和香港（HK$5.4049 亿），以及房地产投资产生的 HK$6.4297 亿。</p>
<p><strong>市值：</strong> HK$77.9B</p>
<p>嘉华国际控股的市值为 HK$77.9 亿，主要收入来自中国大陆和香港的房地产开发。过去五年中，它成功降低了债务与股本比率，保持了相对满意的净债务水平。公司的短期资产显著超过其短期和长期负债，反映出强劲的流动性。然而，最近的收益急剧下降了 58.2%，预测未来三年将进一步下降。尽管交易价格低于估计的公允价值，但其股本回报率仍然较低，仅为 0.9%，由于不稳定的记录，股息稳定性也不确定。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解嘉华国际控股的动态。</li>
<li>在这里了解嘉华国际控股的未来增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis"/></p>
<p>SEHK:173 财务状况分析截至 2025 年 8 月</p>
<h2>中国山水水泥集团 (SEHK:691)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 中国山水水泥集团有限公司是一家投资控股公司，在中华人民共和国制造和销售水泥、熟料、混凝土及相关产品和服务，市值为 HK$38.3 亿。</p>
<p><strong>运营：</strong> 该公司通过制造和交易水泥、熟料和混凝土的业务产生了 CN¥135 亿的收入。</p>
<p><strong>市值：</strong> HK$38.3B</p>
<p>中国山水水泥集团最近的股价波动反映了该行业面临的更广泛挑战。尽管去年实现盈利，但其收益受到大额一次性项目和销售下降的影响，最近半年的收入为 CN¥55.5 亿，而之前为 CN¥65.7 亿。该公司在同一时期报告了 CN¥2.5 亿的净亏损，但相比去年更大亏损有所改善。其债务管理谨慎，净债务与股本比率为 13.2%，尽管短期负债超过资产，面临潜在流动性问题，尤其是在持续的法律问题和治理变更中。</p>
<ul>
<li>点击这里通过我们的详细分析财务健康报告了解中国山水水泥集团的细微差别。</li>
<li>探索历史数据，以跟踪中国山水水泥集团的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis"/></p>
<p>SEHK:691 债务与股本历史及分析截至 2025 年 8 月</p>
<h2>福安药业 (集团) (SZSE:300194)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 福安药业（集团）有限公司从事化学药品的研究、开发、生产和销售，市值为 CN¥58.5 亿。</p>
<p><strong>运营：</strong> 该公司在制药行业部门产生了 CN¥20.5 亿的收入。</p>
<p><strong>市值：</strong> CN¥58.5B</p>
<p>福安药业（集团）有限公司在低价股领域提供了稳定的投资概况，其制药业务收入为 20.5 亿人民币，市值为 58.5 亿人民币。公司拥有经验丰富的管理层和董事会，平均任期分别为 14.3 年和 3.7 年，支持战略的连续性。短期资产充足覆盖短期和长期负债，而运营现金流也能充分覆盖 20% 的债务义务。尽管去年盈利增长为负，但利润率从 9.7% 提高至 11%，显示出在更广泛的制药行业环境挑战中运营的韧性。</p>
<ul>
<li>点击这里查看福安药业（集团）的全面资产负债表健康报告。</li>
<li>通过我们的公司历史业绩报告，深入了解福安药业（集团）过去的趋势和表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis"/></p>
<p>SZSE:300194 财务状况分析截至 2025 年 8 月</p>
<h2>抓住机会</h2>
<ul>
<li>点击开始探索其余 974 只亚洲低价股。</li>
<li>对其他可能性感兴趣？稀土金属是大多数高科技设备、军事和防御系统以及电动车的原材料。全球竞赛正在进行，以确保这些关键矿物的供应。抢先发现这 27 只稀土金属股票，它们是为数不多的开采这一重要战略资源的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

山水水泥

福安药业

<p>亚洲市场正吸引投资者的关注，因为在贸易政策和货币调整变化的背景下，投资者开始关注低价股。值得注意的低价股包括嘉华国际控股、中国山水水泥集团和福安药业（集团），它们的市值和财务健康评级各不相同。嘉华的市值为 77.9 亿港元，但面临盈利下降的问题。中国山水的市值为 38.3 亿港元，价格波动较大，并且最近出现了净亏损。福安药业的估值为 58.5 亿人民币，尽管盈利增长为负，但显示出运营韧性</p>

<p>As global markets navigate a landscape marked by shifting trade policies and monetary adjustments, the Asian market continues to capture attention with its diverse economic activities and robust stock performances. Amidst this backdrop, penny stocks—though an older term—remain a focal point for investors seeking potential growth in smaller or newer companies. By identifying those with strong financial health, investors can uncover opportunities that balance risk with promising returns.</p>
<div class="lb-trans"><p>随着全球市场在不断变化的贸易政策和货币调整中航行，亚洲市场凭借其多样的经济活动和强劲的股票表现继续吸引关注。在这样的背景下，虽然 “便士股票” 是一个较老的术语，但仍然是投资者寻求小型或新兴公司潜在增长的焦点。通过识别那些财务健康状况良好的公司，投资者可以发现平衡风险与潜在回报的机会。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亚洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 977 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲便士股票筛选器的 977 只股票完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选出的显著股票。</p>
</div><h2>K. Wah International Holdings (SEHK:173)</h2>
<div class="lb-trans"><h2>嘉华国际控股 (SEHK:173)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> K. Wah International Holdings Limited is an investment holding company involved in property development and investment in Hong Kong and Mainland China, with a market capitalization of approximately HK$7.79 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 嘉华国际控股有限公司是一家投资控股公司，涉及香港和中国大陆的房地产开发和投资，市值约为 HK$77.9 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from property development in Mainland China (HK$5.91 billion) and Hong Kong (HK$540.49 million), along with property investment generating HK$642.97 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自中国大陆的房地产开发（HK$59.1 亿）和香港（HK$5.4049 亿），以及房地产投资产生的 HK$6.4297 亿。</p>
</div><p><strong>Market Cap:</strong> HK$7.79B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$77.9B</p>
</div><p>K. Wah International Holdings, with a market capitalization of HK$7.79 billion, derives substantial revenue from property development in Mainland China and Hong Kong. It has managed to reduce its debt-to-equity ratio over the past five years, maintaining a satisfactory net debt level relative to equity. The company's short-term assets significantly exceed both its short- and long-term liabilities, reflecting strong liquidity. However, recent earnings have declined sharply by 58.2%, with forecasts indicating further declines over the next three years. Despite trading below estimated fair value, its return on equity remains low at 0.9%, and dividend stability is uncertain due to an unstable track record.</p>
<div class="lb-trans"><p>嘉华国际控股的市值为 HK$77.9 亿，主要收入来自中国大陆和香港的房地产开发。过去五年中，它成功降低了债务与股本比率，保持了相对满意的净债务水平。公司的短期资产显著超过其短期和长期负债，反映出强劲的流动性。然而，最近的收益急剧下降了 58.2%，预测未来三年将进一步下降。尽管交易价格低于估计的公允价值，但其股本回报率仍然较低，仅为 0.9%，由于不稳定的记录，股息稳定性也不确定。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of K. Wah International Holdings.</li>
<li>Learn about K. Wah International Holdings' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解嘉华国际控股的动态。</li>
<li>在这里了解嘉华国际控股的未来增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis"/></p>
<p>SEHK:173 Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:173 财务状况分析截至 2025 年 8 月</p>
</div><h2>China Shanshui Cement Group (SEHK:691)</h2>
<div class="lb-trans"><h2>中国山水水泥集团 (SEHK:691)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> China Shanshui Cement Group Limited is an investment holding company that manufactures and sells cement, clinker, concrete, and related products and services in the People's Republic of China, with a market cap of HK$3.83 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中国山水水泥集团有限公司是一家投资控股公司，在中华人民共和国制造和销售水泥、熟料、混凝土及相关产品和服务，市值为 HK$38.3 亿。</p>
</div><p><strong>Operations:</strong> The company generates CN¥13.50 billion in revenue from its operations in manufacturing and trading cement, clinker, and concrete.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过制造和交易水泥、熟料和混凝土的业务产生了 CN¥135 亿的收入。</p>
</div><p><strong>Market Cap:</strong> HK$3.83B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$38.3B</p>
</div><p>China Shanshui Cement Group has seen a volatile share price recently, reflecting broader challenges in the sector. Despite becoming profitable last year, its earnings have been impacted by large one-off items and declining sales, with recent half-year revenue at CN¥5.55 billion compared to CN¥6.57 billion previously. The company reported a net loss of CN¥250 million for the same period but has improved from a larger loss last year. Its debt management is prudent with a satisfactory net debt to equity ratio of 13.2%, though short-term liabilities exceed assets, posing potential liquidity concerns amidst ongoing legal issues and governance changes.</p>
<div class="lb-trans"><p>中国山水水泥集团最近的股价波动反映了该行业面临的更广泛挑战。尽管去年实现盈利，但其收益受到大额一次性项目和销售下降的影响，最近半年的收入为 CN¥55.5 亿，而之前为 CN¥65.7 亿。该公司在同一时期报告了 CN¥2.5 亿的净亏损，但相比去年更大亏损有所改善。其债务管理谨慎，净债务与股本比率为 13.2%，尽管短期负债超过资产，面临潜在流动性问题，尤其是在持续的法律问题和治理变更中。</p>
</div><ul>
<li>Click here to discover the nuances of China Shanshui Cement Group with our detailed analytical financial health report.</li>
<li>Explore historical data to track China Shanshui Cement Group's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的详细分析财务健康报告了解中国山水水泥集团的细微差别。</li>
<li>探索历史数据，以跟踪中国山水水泥集团的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis"/></p>
<p>SEHK:691 Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:691 债务与股本历史及分析截至 2025 年 8 月</p>
</div><h2>Fuan Pharmaceutical (Group) (SZSE:300194)</h2>
<div class="lb-trans"><h2>福安药业 (集团) (SZSE:300194)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Fuan Pharmaceutical (Group) Co., Ltd. is engaged in the research, development, production, and sale of chemical drugs in China with a market cap of CN¥5.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 福安药业（集团）有限公司从事化学药品的研究、开发、生产和销售，市值为 CN¥58.5 亿。</p>
</div><p><strong>Operations:</strong> The company generates CN¥2.05 billion in revenue from its pharmaceutical industry segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司在制药行业部门产生了 CN¥20.5 亿的收入。</p>
</div><p><strong>Market Cap:</strong> CN¥5.85B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥58.5B</p>
</div><p>Fuan Pharmaceutical (Group) Co., Ltd. offers a stable investment profile within the penny stock segment, with its CN¥2.05 billion revenue from pharmaceuticals and a market cap of CN¥5.85 billion. The company boasts seasoned management and board teams, with average tenures of 14.3 and 3.7 years respectively, supporting strategic continuity. Short-term assets comfortably cover both short- and long-term liabilities, while operating cash flow adequately covers debt obligations at 20%. Despite negative earnings growth last year, profit margins improved to 11% from 9.7%, indicating operational resilience amid challenges in the broader pharmaceutical industry landscape.</p>
<div class="lb-trans"><p>福安药业（集团）有限公司在低价股领域提供了稳定的投资概况，其制药业务收入为 20.5 亿人民币，市值为 58.5 亿人民币。公司拥有经验丰富的管理层和董事会，平均任期分别为 14.3 年和 3.7 年，支持战略的连续性。短期资产充足覆盖短期和长期负债，而运营现金流也能充分覆盖 20% 的债务义务。尽管去年盈利增长为负，但利润率从 9.7% 提高至 11%，显示出在更广泛的制药行业环境挑战中运营的韧性。</p>
</div><ul>
<li>Navigate through the intricacies of Fuan Pharmaceutical (Group) with our comprehensive balance sheet health report here.</li>
<li>Gain insights into Fuan Pharmaceutical (Group)'s past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里查看福安药业（集团）的全面资产负债表健康报告。</li>
<li>通过我们的公司历史业绩报告，深入了解福安药业（集团）过去的趋势和表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis"/></p>
<p>SZSE:300194 Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SZSE:300194 财务状况分析截至 2025 年 8 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Click through to start exploring the rest of the 974 Asian Penny Stocks now.</li>
<li>Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击开始探索其余 974 只亚洲低价股。</li>
<li>对其他可能性感兴趣？稀土金属是大多数高科技设备、军事和防御系统以及电动车的原材料。全球竞赛正在进行，以确保这些关键矿物的供应。抢先发现这 27 只稀土金属股票，它们是为数不多的开采这一重要战略资源的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

亚洲市场亮点：2025 年 8 月值得关注的低价股